Chang-Peng Zhu

Title: Chang-Peng Zhu: Innovator in Pharmaceutical Applications for Portal Hypertension

Introduction

Chang-Peng Zhu is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of portal hypertension. His innovative work has the potential to improve the quality of life for patients suffering from this condition.

Latest Patents

Chang-Peng Zhu holds a patent titled "Application of 5-hydroxytryptamine receptor 1A in preparing drug for portal hypertension." This invention relates to the technical field of pharmaceuticals and describes the application of a 5-hydroxytryptamine receptor 1A in preparing a drug for portal hypertension. The invention achieved a significant decrease in portal venous pressure in model rats with cirrhotic portal hypertension through the administration of an HTR1A inhibitor WAY100635 or alverine. This novel approach provides a potential treatment for various symptoms associated with portal hypertension syndrome.

Career Highlights

Chang-Peng Zhu is affiliated with the Second Affiliated Hospital of the Second Military Medical University. His work in this institution has allowed him to focus on innovative research and development in the pharmaceutical field. His dedication to advancing medical treatments is evident in his patent and ongoing research efforts.

Collaborations

Chang-Peng Zhu has collaborated with notable colleagues, including Wei-Fen Xie and Xin Zhang. These partnerships have contributed to the advancement of research in the area of portal hypertension and related pharmaceutical applications.

Conclusion

Chang-Peng Zhu's contributions to the field of pharmaceuticals, particularly through his patent on the application of 5-hydroxytryptamine receptor 1A, highlight his role as an innovator in the treatment of portal hypertension. His work has the potential to significantly impact patient care and treatment options in this area.